AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?
Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.
Open original sourceLoading market dashboard
Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.
Open original source